Home - Translational Lung Cancer Research

Reviewer of the Month (2020-21)

Over the years, many TLCR reviewers have made outstanding contributions to the peer review process. They demonstrated professional effort and enthusiasm in their reviews and provided comments that genuinely help the authors to enhance their work.

Hereby, we would like to highlight some of our outstanding reviewers, with a brief interview of their thoughts and insights as a reviewer. Allow us to express our heartfelt gratitude for their tremendous effort and valuable contributions to the scientific process.

Multimodal Management of Locally Advanced N2 Non-small Cell Lung Cancer

This special series on “Multimodal management of locally advanced N2 non-small cell lung cancer” is edited by Dr. Mariano Provencio.

Implementation of CT-based screening of lung cancer

In this special series, a group of the most outstanding experts and researchers of all aspects of lung cancer screening answers the most important questions about the introduction of a screening program as well as the development of this new field of medicine.

TLCR Annual Report 2020

Welcome to the 2020 annual report for Translational Lung Cancer Research. In 2020, the TLCR has continued its mission to increase the quality and impact of the journal, and to provide readers with a novel, well-organized, informative, enlightening and educational journal.

We would like to sincerely thank our Editorial Board Members, Guest editors, Reviewers, Authors, Readers for all your supports and contributions to TLCR in 2020, and we look forward to continuing our work with you in the new year.

Translational Lung Cancer Research to publish monthly beginning in January 2021

Since its initiation in 2012, Translational Lung Cancer Research (TLCR) has been developing at a speedy pace with increasing readership and citations. In order to better serve the growing needs of readers and authors, the TLCR will move from a bimonthly to a monthly publication schedule beginning in January 2021.

Looking for Chimeras in NSCLC: Widen Therapeutic Options Targeting Oncogenic Fusions

A deeper understanding of innate/acquired resistance to the different TKIs already available for clinical use and the development of new effective treatment strategies to overcome it, represent a current area of intense investigation and has been extensively debated within different papers published in the series.

Lung Cancer Multidisciplinary Care

The papers in this series explore important aspects of MDT care including the early introduction of palliative care, the impact on advanced disease, optimal staging in the context of the MDT, gaps in our understanding of how to best implement and test the effects of MDTs, patient outcomes associated with MDT care, lung cancer surgery in the MDT setting and optimized approaches to data systems for the MDT.

New Developments in Lung Cancer Diagnosis and Pathological Patient Management Strategies

During the last decade we have seen many changes in the field of Lung Pathology, and had to keep with the immense progress: new therapy options for lung cancer patients have changed our practice and required to learn from disciplines such as genetics and immunology. The aim of this series is to discuss new developments or already present techniques and confront pathologists with this news, hopefully convincing them to adjust the daily practice accordingly.

New Impact Factor for Translational Lung Cancer Research: 5.132

We are pleased to announce that the Translational Lung Cancer Research (TLCR) has attained its latest impact factor update for the 2019 citation year: 5.132.

‹ ›

Vol 10, No 4 (April, 2021)

About tlcr

Manuscript Submission

AME Editing Service

Reprint & Permission

Advertising

Contact us

General editorial enquiries:
Email: editor@tlcr.org
Copyright related contact:
Email: permissions@amegroups.com
Commercial Sales contact (Reprints, advertising, etc.):
Email: sales@amegroups.com

Original Article

Prognostic impact of PD-1 and PD-L1 expression in malignant pleural mesothelioma: an international multicenter study

Luka Brcic, Thomas Klikovits, Zsolt Megyesfalvi, Berta Mosleh, Katharina Sinn, Richard Hritcu, Viktoria Laszlo, Tanja Cufer, Ales Rozman, Izidor Kern, Katja Mohorcic, Marko Jakopovic, Miroslav Samarzija, Sven Seiwerth, Vitezslav Kolek, Ondřej Fischer, Petr Jakubec, Jozef Škarda, Balazs Gieszer, Balazs Hegedus, Janos Fillinger, Ferenc Renyi-Vamos, Anna Buder, Agnes Bilecz, Walter Berger, Michael Grusch, Konrad Hoetzenecker, Walter Klepetko, Mir Alireza Hoda, Martin Filipits, Balazs Dome

PDF Pages: 1594-1607 Full Text Reporting Checklist Data Sharing Statement Peer Review File COI Form Open Access

Transbronchial microwave ablation of lung nodules with electromagnetic navigation bronchoscopy guidance—a novel technique and initial experience with 30 cases

Joyce W. Y. Chan, Rainbow W. H. Lau, Jenny C. L. Ngai, Carita Tsoi, Cheuk Man Chu, Tony S. K. Mok, Calvin S. H. Ng

PDF Pages: 1608-1622 Full Text Reporting Checklist Data Sharing Statement Peer Review File COI Form Open Access

Plasma pre-treatment T790M relative allelic frequency in patients with advanced EGFR-mutated non-small cell lung cancer predicts treatment response to subsequent-line osimertinib

Pei N. Ding, Tara L. Roberts, Wei Chua, Therese M. Becker, Nicole Caixeiro, Paul de Souza, Bo Gao, Chee K. Lee, Malinda Itchins, Helen Westman, Stephen Clarke, Prunella Blinman, Steven Kao, Tom John, Jose L. Leal, Victoria J. Bray

PDF Pages: 1623-1634 Full Text Reporting Checklist Data Sharing Statement Peer Review File COI Form Open Access

Is flexible bronchoscopy necessary in the preoperative workup of patients with peripheral cT1N0 subsolid lung cancer? —a prospective multi-center cohort study

Ting Ye, Zongwei Chen, Dongchun Ma, Sufeng Chen, Guozhan Xia, Yiliang Zhang, Hang Li, Yang Zhang, Xiaoyang Luo, Longsheng Miao, Longfei Ma, Yihua Sun, Yunjian Pan, Hong Hu, Yawei Zhang, Jiaqing Xiang, Longlong Shao, Haoxuan Wu, Bin Li, Qingyuan Huang, Xiao Ma, Difan Zheng, Shanbo Zheng, Chongze Yuan, Tao Yu, Yunyun Lu, Yuan Li, Qiao Li, Yajia Gu, Shengping Wang, Di Ge, Jie Gu, Feng Zhu, Jingshun Zhang, Fudong Wang, Yuan Weng, Chunyi Jia, Shilei Liu, Wenqun Xing, Kaihong Lin, Shaoqing Tang, Bin Qian, Michael Hsin, Haiquan Chen

PDF Pages: 1635-1641 Full Text Reporting Checklist Data Sharing Statement Peer Review File COI Form Open Access

Impact of docetaxel plus ramucirumab on metastatic site in previously treated patients with non-small cell lung cancer: a multicenter retrospective study

Kinnosuke Matsumoto, Akihiro Tamiya, Yoshinobu Matsuda, Yoshihiko Taniguchi, Shinji Atagi, Hayato Kawachi, Motohiro Tamiya, Satoshi Tanizaki, Junji Uchida, Kiyonobu Ueno, Takafumi Yanase, Hidekazu Suzuki, Tomonori Hirashima

PDF Pages: 1642-1652 Full Text Reporting Checklist Data Sharing Statement Peer Review File COI Form Open Access

EPAC-lung: European pooled analysis of the prognostic value of circulating tumour cells in small cell lung cancer

Victoria Foy, Colin R. Lindsay, Alexandra Carmel, Fabiola Fernandez-Gutierrez, Matthew G. Krebs, Lynsey Priest, Mathew Carter, Harry J. M. Groen, T. Jeroen. N. Hiltermann, Antonella de Luca, Francoise Farace, Benjamin Besse, Leon Terstappen, Elisabetta Rossi, Alessandro Morabito, Francesco Perrone, Andrew Renehan, Corinne Faivre-Finn, Nicola Normanno, Caroline Dive, Fiona Blackhall, Stefan Michiels

PDF Pages: 1653-1665 Full Text Reporting Checklist Data Sharing Statement COI Form Open Access

Conventional and semi-automatic histopathological analysis of tumor cell content for multigene sequencing of lung adenocarcinoma

Daniel Kazdal, Eugen Rempel, Cristiano Oliveira, Michael Allgäuer, Alexander Harms, Kerstin Singer, Elke Kohlwes, Steffen Ormanns, Ludger Fink, Jörg Kriegsmann, Michael Leichsenring, Katharina Kriegsmann, Fabian Stögbauer, Luca Tavernar, Jonas Leichsenring, Anna-Lena Volckmar, Rémi Longuespée, Hauke Winter, Martin Eichhorn, Claus Peter Heußel, Felix Herth, Petros Christopoulos, Martin Reck, Thomas Muley, Wilko Weichert, Jan Budczies, Michael Thomas, Solange Peters, Arne Warth, Peter Schirmacher, Albrecht Stenzinger, Mark Kriegsmann

PDF Pages: 1666-1678 Full Text Reporting Checklist Data Sharing Statement COI Form Open Access

Identification of PD-1 ligands: PD-L1 and PD-L2 on macrophages in lung cancer milieu by flow cytometry

Iwona Kwiecień, Elżbieta Rutkowska, Małgorzata Polubiec-Kownacka, Agata Raniszewska, Piotr Rzepecki, Joanna Domagała-Kulawik

PDF Pages: 1679-1689 Full Text Reporting Checklist Data Sharing Statement COI Form Open Access

A nomogram for predicting overall survival in patients with resected non-small cell lung cancer treated with chemotherapy

Yuan Zeng, Nicholas Mayne, Chi-Fu Jeffrey Yang, Jun Liu, Fei Cui, Jingpei Li, Wenhua Liang, Jianxing He, written on behalf of the AME Thoracic Surgery Collaborative Group

PDF Pages: 1690-1699 Full Text Reporting Checklist Peer Review File COI Form Open Access

Blood transfusions may adversely affect survival outcomes of patients with lung cancer: a systematic review and meta-analysis

Sukjoo Cho, Jonghanne Park, Misuk Lee, Dongyup Lee, Horyun Choi, Gahyun Gim, Leeseul Kim, Cyra Y. Kang, Youjin Oh, Pedro Viveiros, Elena Vagia, Michael S. Oh, Geum Joon Cho, Ankit Bharat, Young Kwang Chae

PDF Pages: 1700-1710 Full Text Reporting Checklist COI Form Open Access

Watershed analysis of the target pulmonary artery for real-time localization of non-palpable pulmonary nodules

Xiang-Peng Chu, Zi-Hao Chen, Shao-Min Lin, Jia-Tao Zhang, Zhao-Wen Qiu, Wen-Fang Tang, Rui Fu, Zhen-Bin Qiu, Xue-Ning Yang, Yi-Long Wu, Qiang Nie, Wen-Zhao Zhong

PDF Pages: 1711-1719 Full Text Reporting Checklist Data Sharing Statement COI Form Open Access

Age at first birth and lung cancer: a two-sample Mendelian randomization study

Haoxin Peng, Xiangrong Wu, Yaokai Wen, Xiaoqin Du, Caichen Li, Hengrui Liang, Jinsheng Lin, Jun Liu, Fan Ge, Zhenyu Huo, Jianxing He, Wenhua Liang

PDF Pages: 1720-1733 Full Text Data Sharing Statement COI Form Open Access

Presentation of EGFR mutations in 162 family probands with multiple primary lung cancer

Chunxiang Li, Yalong Wang, Kai Su, Yu Liu, Liyu Wang, Bo Zheng, Na Yan, Dawei Yuan, Yanxiang Zhang, Liyan Xue, Shugeng Gao, Jie He

PDF Pages: 1734-1746 Full Text Reporting Checklist Data Sharing Statement COI Form Open Access

Distinct patterns of somatic genomic alterations and mutational signatures in central and peripheral-type small-cell lung cancer

Lei Wang, Jing Wang, Juanni Hu, Lele Song, Jian Ni, Yayi He, Caicun Zhou

PDF Pages: 1747-1760 Full Text Reporting Checklist Data Sharing Statement COI Form Open Access

Spanish Lung Cancer Group SCAT trial: surgical audit to lymph node assessment based on IASLC recommendations

José Ramón Jarabo Sarceda, Sergio Bolufer Nadal, Roberto Mongil Poce, Pedro López de Castro, Ramón Moreno Balsalobre, Juan Carlos Peñalver Cuesta, Raul Embún Flor, Joaquín Pac Ferrer, Francisco Javier Algar Algar, Antonio Pablo Gámez García, Marcelo F. Jiménez, Jesús Gabriel Sales-Badía, Eva Pereira, Bartomeu Massuti, Mariano Provencio, Florentino Hernando Trancho

PDF Pages: 1761-1772 Full Text Reporting Checklist Data Sharing Statement COI Form Open Access

MicroRNA expression profiling and biomarker validation in treatment-naïve and drug resistant non-small cell lung cancer

Lauren MacDonagh, Michael F. Gallagher, Brendan Ffrench, Claudia Gasch, Steven G. Gray, Marie Reidy, Siobhan Nicholson, Niamh Leonard, Ronan Ryan, Vincent Young, John J. O’Leary, Sinead Cuffe, Stephen P. Finn, Kenneth J. O’Byrne, Martin P. Barr

PDF Pages: 1773-1791 Full Text Data Sharing Statement Peer Review File COI Form Open Access

Genomic evolutionary trajectory of metastatic squamous cell carcinoma of the lung

Arthur Krause, Luca Roma, Thomas Lorber, Tanja Dietsche, Valeria Perrina, David C. Müller, Didier Lardinois, Christian Ruiz, Spasenija Savic Prince, Salvatore Piscuoglio, Charlotte KY Ng, Lukas Bubendorf

PDF Pages: 1792-1803 Full Text Reporting Checklist Data Sharing Statement Peer Review File COI Form Open Access

Role of the epithelial-mesenchymal transition-related circular RNA, circ-10720, in non-small-cell lung cancer

Jara Martín, Joan Josep Castellano, Ramón María Marrades, Jordi Canals, Nuria Viñolas, Tania Díaz, Laureano Molins, Daniel Martinez, Bing Han, Jorge Moisés, Yangyi He, Mariano Monzó, Alfons Navarro

PDF Pages: 1804-1818 Full Text Reporting Checklist Data Sharing Statement COI Form Open Access

Safety and efficacy of anti-PD-1 inhibitors in Chinese patients with advanced lung cancer and hepatitis B virus infection: a retrospective single-center study

Fei Xu, Zhu Zeng, Bing Yan, Yiqi Fu, Yilan Sun, Guangdie Yang, Lingfang Tu, Satoshi Watanabe, Salma K. Jabbour, Sara Bravaccini, Francesca Fanini, Jianying Zhou, Yihong Shen

PDF Pages: 1819-1828 Full Text Reporting Checklist Data Sharing Statement COI Form Open Access

Derivation and validation of a nomogram model for pulmonary thromboembolism in patients undergoing lung cancer surgery

Yuping Li, Lei Shen, Junrong Ding, Dong Xie, Jian Yang, Yanfeng Zhao, Angelo Carretta, René Horsleben Petersen, Sebastien Gilbert, Yasuhiro Hida, Servet Bölükbas, Hiran C. Fernando, Gening Jiang, Yuming Zhu

PDF Pages: 1829-1840 Full Text Reporting Checklist Data Sharing Statement COI Form Open Access

Let-7b-3p inhibits tumor growth and metastasis by targeting the BRF2-mediated MAPK/ERK pathway in human lung adenocarcinoma

Yongmeng Li, Rui Dong, Ming Lu, Chuanle Cheng, Zitong Feng, Renchang Zhao, Jinghui Liang, Jingyi Han, Jin Jiang, Meng Xu-Welliver, Stéphane Renaud, Hui Tian

PDF Pages: 1841-1856 Full Text Reporting Checklist Data Sharing Statement COI Form Open Access

Targeting histone deacetylase enhances the therapeutic effect of Erastin-induced ferroptosis in EGFR-activating mutant lung adenocarcinoma

Tuo Zhang, Beibei Sun, Chenxi Zhong, Ke Xu, Zhexin Wang, Paul Hofman, Tatsuya Nagano, Antoine Legras, Daniel Breadner, Biagio Ricciuti, Duilio Divisi, Ralph A. Schmid, Ren-Wang Peng, Haitang Yang, Feng Yao

PDF Pages: 1857-1872 Full Text Reporting Checklist Data Sharing Statement COI Form Open Access

Anlotinib combined with gefitinib can significantly improve the proliferation of epidermal growth factor receptor-mutant advanced non-small cell lung cancer in vitro and in vivo

Tao Li, Yuxian Qian, Chenfei Zhang, Junji Uchino, Mariano Provencio, Yan Wang, Xiangrong Shi, Yan Zhang, Xiaodong Zhang

PDF Pages: 1873-1888 Full Text Reporting Checklist Data Sharing Statement COI Form Open Access

Review Article

A narrative review of tumor-associated macrophages in lung cancer: regulation of macrophage polarization and therapeutic implications

Sahar Sadat Sedighzadeh, Amin Pastaki Khoshbin, Sepideh Razi, Mahsa Keshavarz-Fathi, Nima Rezaei

PDF Pages: 1889-1916 Full Text Reporting Checklist Peer Review File COI Form Open Access

Case Report

Immune-checkpoint inhibitors for lung cancer patients amid the COVID-19 pandemic: a case report of severe meningoencephalitis after switching to an extended-interval higher flat-dose nivolumab regimen

Anna Pous, Cristina Izquierdo, Marc Cucurull, Silvia Sánchez, Clara Lezcano, Marta Domenech, Laia Llobera, Andrea Plaja, Teresa Moran

PDF Pages: 1917-1923 Full Text Reporting Checklist Peer Review File COI Form Open Access

Editorial Commentary

From CheckMate 227 to CheckMate 9LA: rethinking the status of chemotherapy in the immunotherapy era—chemo-free or chemo-reform?

Haiyi Deng, Chengzhi Zhou

PDF Pages: 1924-1927 Full Text COI Form Open Access

Editorial on Radiotherapy in Thoracic Malignancies¹

Radiotherapy in thoracic malignancies: the preface

Jacek Jassem, Rafał Dziadziuszko

PDF Pages: 1928-1929 Full Text COI Form Open Access

Review Article on Radiotherapy in Thoracic Malignancies¹

Stereotactic radiotherapy for early stage non-small cell lung cancer: current standards and ongoing research

Eugenia Vlaskou Badra, Michael Baumgartl, Silvia Fabiano, Aurélien Jongen, Matthias Guckenberger

PDF Pages: 1930-1949 Full Text Peer Review File COI Form Open Access

Preoperative and postoperative radiotherapy (RT) for non-small cell lung cancer: still an open question

Paul Van Houtte, Luigi Moretti, Florian Charlier, Martine Roelandts, Dirk Van Gestel

PDF Pages: 1950-1959 Full Text Peer Review File COI Form Open Access

Original Article on Radiotherapy in Thoracic Malignancies¹

Stage III N2 non-small cell lung cancer treatment: decision-making among surgeons and radiation oncologists

Markus Glatzer, Pawel Leskow, Francesca Caparrotti, Olgun Elicin, Markus Furrer, Franco Gambazzi, André Dutly, Hans Gelpke, Matthias Guckenberger, Jürg Heuberger, Rolf Inderbitzi, Stefano Cafarotti, Wolfram Karenovics, Peter Kestenholz, Gregor Jan Kocher, Peter Kraxner, Thorsten Krueger, Francesco Martucci, Christoph Oehler, Mahmut Ozsahin, Alexandros Papachristofilou, Dirk Wagnetz, Kathrin Zaugg, Daniel Zwahlen, Isabelle Opitz, Paul Martin Putora

PDF Pages: 1960-1968 Full Text Data Sharing Statement Peer Review File COI Form Open Access

Review Article on Radiotherapy in Thoracic Malignancies¹

Dose and fractionation schedules in radiotherapy for non-small cell lung cancer

Lucyna Kepka, Joanna Socha

PDF Pages: 1969-1982 Full Text Peer Review File COI Form Open Access

Challenges in the target volume definition of lung cancer radiotherapy

Susan Mercieca, José S. A. Belderbos, Marcel van Herk

PDF Pages: 1983-1998 Full Text Peer Review File COI Form Open Access

Evolving target volume concepts in locally advanced non-small cell lung cancer

Ursula Nestle, Cecile Le Pechoux, Dirk De Ruysscher

PDF Pages: 1999-2010 Full Text Peer Review File COI Form Open Access

Tumour motion management in lung cancer: a narrative review

Angela Botticella, Antonin Levy, Guillaume Auzac, Isabelle Chabert, Céline Berthold, Cécile Le Pechoux

PDF Pages: 2011-2017 Full Text Reporting Checklist Peer Review File COI Form Open Access

Concurrent chemoradiotherapy for stage III non-small-cell lung cancer: recent progress and future perspectives (a narrative review)

Małgorzata Łazar-Poniatowska, Artur Bandura, Rafał Dziadziuszko, Jacek Jassem

PDF Pages: 2018-2031 Full Text Reporting Checklist Peer Review File COI Form Open Access

Combining radiotherapy with targeted therapies in non-small cell lung cancer: focus on anti-EGFR, anti-ALK and anti-angiogenic agents

Anna Wrona, Rafał Dziadziuszko, Jacek Jassem

PDF Pages: 2032-2047 Full Text COI Form Open Access

An overview of the published and running randomized phase 3 clinical results of radiotherapy in combination with immunotherapy

Ben G. L. Vanneste, Evert J. Van Limbergen, Kobe Reynders, Dirk De Ruysscher

PDF Pages: 2048-2058 Full Text COI Form Open Access

Thoracic radiotherapy in small cell lung cancer—a narrative review

Antonin Levy, Angela Botticella, Cécile Le Péchoux, Corinne Faivre-Finn

PDF Pages: 2059-2070 Full Text Reporting Checklist COI Form Open Access

Prophylactic cranial irradiation in SCLC

Rafal Suwinski

PDF Pages: 2071-2078 Full Text COI Form Open Access

Controversies in the role of radiotherapy in pleural mesothelioma

Gerard G. Hanna, Thomas John, David L. Ball

PDF Pages: 2079-2087 Full Text Peer Review File COI Form Open Access

Radiotherapy for thymic epithelial tumours: a review

Krisztian Süveg, Paul Martin Putora, Markus Joerger, Thomas Iseli, Galina Farina Fischer, Karlheinz Ammann, Markus Glatzer

PDF Pages: 2088-2100 Full Text Peer Review File COI Form Open Access

Erratum

Erratum to latest CT technologies in lung cancer screening: protocols and radiation dose reduction

Editorial Office

PDF Pages: 2101-2102 Full Text Open Access

Disclosure:

1. The series “Oligometastatic NSCLC: definition and treatment opportunities” was commissioned by the Editorial office, Translational Lung Cancer Research without any sponsorship or funding. Jacek Jassem and Rafał Dziadziuszko served as the unpaid Guest Editors for the series.

Review Article

Targeted therapy for non-small cell lung cancer: current standards and the promise of the future

Bryan A. Chan, Brett G.M. Hughes

Beyond ALK-RET, ROS1 and other oncogene fusions in lung cancer

Takashi Kohno, Takashi Nakaoku, Koji Tsuta, Katsuya Tsuchihara, Shingo Matsumoto, Kiyotaka Yoh, Koichi Goto

Global trends of lung cancer mortality and smoking prevalence

Farhad Islami, Lindsey A. Torre, Ahmedin Jemal

Known and putative mechanisms of resistance to EGFR targeted therapies in NSCLC patients with EGFR mutations—a review

Erin L. Stewart, Samuel Zhixing Tan, Geoffrey Liu, Ming-Sound Tsao

Tackling ALK in non-small cell lung cancer: the role of novel inhibitors

Francesco Facchinetti, Marcello Tiseo, Massimo Di Maio, Paolo Graziano, Emilio Bria, Giulio Rossi, Silvia Novello

Circulating tumor cells versus circulating tumor DNA in lung cancer—which one will win?

Silvia Calabuig-Fariñas, Eloísa Jantus-Lewintre, Alejandro Herreros-Pomares, Carlos Camps

Editorial

Whacking a mole-cule: clinical activity and mechanisms of resistance to third generation EGFR inhibitors in EGFR mutated lung cancers with EGFR-T790M

Daniel B. Costa, Susumu S. Kobayashi

Review Articles

Management of ground-glass opacities: should all pulmonary lesions with ground-glass opacity be surgically resected?

Yoshihisa Kobayashi, Tetsuya Mitsudomi

KRAS mutant NSCLC, a new opportunity for the synthetic lethality therapeutic approach

Javier de Castro Carpeño, Cristóbal Belda-Iniesta

Review Article on Lung Cancer Diagnostics and Treatments 2015: A Renaissance of Patient Care

Immune checkpoint inhibitors in clinical practice: update on management of immune-related toxicities

Jeryl Villadolid, Asim Amin

Review Article

Targeted therapy for non-small cell lung cancer: current standards and the promise of the future

Bryan A. Chan, Brett G.M. Hughes

Known and putative mechanisms of resistance to EGFR targeted therapies in NSCLC patients with EGFR mutations—a review

Erin L. Stewart, Samuel Zhixing Tan, Geoffrey Liu, Ming-Sound Tsao

Global trends of lung cancer mortality and smoking prevalence

Farhad Islami, Lindsey A. Torre, Ahmedin Jemal

Recurrence after surgery in patients with NSCLC

Hidetaka Uramoto, Fumihiro Tanaka

Beyond ALK-RET, ROS1 and other oncogene fusions in lung cancer

Takashi Kohno, Takashi Nakaoku, Koji Tsuta, Katsuya Tsuchihara, Shingo Matsumoto, Kiyotaka Yoh, Koichi Goto

Non-small cell lung cancer: current treatment and future advances

Cecilia Zappa, Shaker A. Mousa

Phosphatidylinositol 3-kinase-AKT-mammalian target of rapamycin (PI3K-Akt-mTOR) signaling pathway in non-small cell lung cancer

Po Yee Yip

Lung cancer molecular epidemiology in China: recent trends

Caicun Zhou

The role of the immune system in non-small cell lung carcinoma and potential for therapeutic intervention

Joanna Domagala-Kulawik

Concordance of IHC, FISH and RT-PCR for EML4-ALK rearrangements

Cristina Teixidó, Niki Karachaliou, Vicente Peg, Ana Gimenez-Capitan, Rafael Rosell

ALK and crizotinib: after the honeymoon…what else? Resistance mechanisms and new therapies to overcome it

Christian Rolfo, Francesco Passiglia, Marta Castiglia, Luis E. Raez, Paul Germonpre, Ignacio Gil-Bazo, Karen Zwaenepoel, Annemieke De Wilde, Giuseppe Bronte, Antonio Russo, Jan P. Van Meerbeeck, Paul Van Schil, Patrick Pauwels

Highlighted Reports in European Lung Cancer Conference

Preoperative mediastinal lymph node staging for non-small cell lung cancer: 2014 update of the 2007 ESTS guidelines

Paul De Leyn, Christophe Dooms, Jaroslaw Kuzdzal, Didier Lardinois, Bernward Passlick, Ramon Rami-Porta, Akif Turna, Paul Van Schil, Frederico Venuta, David Waller, Walter Weder, Marcin Zielinski

Review Article on Lung Cancer Diagnostics and Treatments 2015: A Renaissance of Patient Care

Immune checkpoint inhibitors in clinical practice: update on management of immune-related toxicities

Jeryl Villadolid, Asim Amin

Circulating DNA in diagnosis and monitoring EGFR gene mutations in advanced non-small cell lung cancer

Paola Bordi, Marzia Del Re, Romano Danesi, Marcello Tiseo

Novel radiotherapy approaches for lung cancer: combining radiation therapy with targeted and immunotherapies

Charles B. Simone II, Stuart H. Burri, John H. Heinzerling

Angiogenesis inhibition as a therapeutic strategy in non-small cell lung cancer (NSCLC)

Richard D. Hall, Tri M. Le, Daniel E. Haggstrom, Ryan D. Gentzler

Original Article

Prognostic value of Twist in lung cancer: systematic review and meta-analysis

Junli Zeng, Ping Zhan, Guannan Wu, Wen Yang, Wenjun Liang, Tangfeng Lv, Yong Song

BRAF mutations in non-small cell lung cancer

Peter P. Luk, Bing Yu, Chiu Chin Ng, Belinda Mercorella, Christina Selinger, Trina Lum, Steven Kao, Sandra A. O’Toole, Wendy A. Cooper

The suitability of small biopsy and cytology specimens for EGFR and other mutation testing in non-small cell lung cancer

Shu Wang, Bing Yu, Chiu Chin Ng, Belinda Mercorella, Christina I. Selinger, Sandra A. O’Toole, Wendy A. Cooper

Itraconazole can inhibit malignant pleural effusion by suppressing lymphangiogenesis in mice

Yunfen Wang, Yanwen Yao, Hongbin Liu, Xingqun Ma, Tangfeng Lv, Dongmei Yuan, Xinwu Xiao, Jie Yin, Yong Song

Ratio of maximum standardized uptake value to primary tumor size is a prognostic factor in patients with advanced non-small cell lung cancer

Fangfang Chen, Yanwen Yao, Chunyan Ma, Xingqun Ma, Zhaofeng Wang, Tangfeng Lv, Xinwu Xiao, Jie Yin, Yong Song

Advanced proton beam dosimetry part II: Monte Carlo vs. pencil beam-based planning for lung cancer

Dominic Maes, Jatinder Saini, Jing Zeng, Ramesh Rengan, Tony Wong, Stephen R. Bowen

The cytokinesis-blocked micronucleus assay as a novel biomarker for selection of lung cancer screening participants

Randa A. El-Zein, Carol J. Etzel, Reginald F. Munden

The use of TCP based EUD to rank and compare lung radiotherapy plans: in-silico study to evaluate the correlation between TCP with physical quality indices

Abdulhamid Chaikh, Jacques Balosso

Review Article

Beyond ALK-RET, ROS1 and other oncogene fusions in lung cancer

Takashi Kohno, Takashi Nakaoku, Koji Tsuta, Katsuya Tsuchihara, Shingo Matsumoto, Kiyotaka Yoh, Koichi Goto

Overview of clinicopathologic features of ALK-rearranged lung adenocarcinoma and current diagnostic testing for ALK rearrangement

Hyojin Kim, Jin-Haeng Chung

Neoadjuvant and adjuvant epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) therapy for lung cancer

Haoran Zhai, Wenzhao Zhong, Xuening Yang, Yi-Long Wu

Known and putative mechanisms of resistance to EGFR targeted therapies in NSCLC patients with EGFR mutations—a review

Erin L. Stewart, Samuel Zhixing Tan, Geoffrey Liu, Ming-Sound Tsao

Clinical trials for lung cancer in China

Fei-Yu Niu, Wen-Zhao Zhong, Qing Zhou, Yi-Long Wu

Recurrence after surgery in patients with NSCLC

Hidetaka Uramoto, Fumihiro Tanaka

Prognostic markers in lung cancer: is it ready for prime time?

Chang-Qi Zhu, Ming-Sound Tsao

Potential biomarkers for lung cancer screening

Gabriella Sozzi, Mattia Boeri

Particle therapy in non-small cell lung cancer

Zhongxing Liao, Charles B. Simone II

Computer Aided Nodule Analysis and Risk Yield (CANARY) characterization of adenocarcinoma: radiologic biopsy, risk stratification and future directions

Ryan Clay, Srinivasan Rajagopalan, Ronald Karwoski, Fabien Maldonado, Tobias Peikert, Brian Bartholmai

Immunotherapy and radiation therapy for operable early stage and locally advanced non-small cell lung cancer

Neil K. Taunk, Andreas Rimner, Melissa Culligan, Joseph S. Friedberg, Julie Brahmer, Jamie Chaft

Combining immunotherapy and radiation therapy for small cell lung cancer and thymic tumors

Suchit H. Patel, Andreas Rimner, Roger B. Cohen

Intraoperative near-infrared imaging of mesothelioma

Gregory Thomas Kennedy, Andrew Newton, Jarrod Predina, Sunil Singhal

BAP1, a tumor suppressor gene driving malignant mesothelioma

Mitchell Cheung, Joseph R. Testa

Uncovering the immune tumor microenvironment in non-small cell lung cancer to understand response rates to checkpoint blockade and radiation

Jonathan E. Schoenhals, Steven N. Seyedin, Clark Anderson, Eric D. Brooks, Yun R. Li, Ahmed I. Younes, Sharareh Niknam, Ailin Li, Hampartsoum B. Barsoumian, Maria Angelica Cortez, James W. Welsh

Diagnostic and prognostic biomarkers for malignant mesothelioma: an update

Zhongjian Chen, Giovanni Gaudino, Harvey I. Pass, Michele Carbone, Haining Yang

Immunotherapy for malignant pleural mesothelioma: current status and future directions

Jordan Dozier, Hua Zheng, Prasad S. Adusumilli

Biology and clinical significance of circulating tumor cell subpopulations in lung cancer

Linda O’Flaherty, Harriet Wikman, Klaus Pantel

Routine clinical use of circulating tumor cells for diagnosis of mutations and chromosomal rearrangements in non-small cell lung cancer—ready for prime-time?

Emma Pailler, Vincent Faugeroux, Marianne Oulhen, Cyril Catelain, Françoise Farace

Challenges and unanswered questions for the next decade of circulating tumour cell research in lung cancer

Sumitra Mohan, Francesca Chemi, Ged Brady

Biophysical technologies for understanding circulating tumor cell biology and metastasis

Derrick W. Su, Jorge Nieva

Clinical utility of circulating tumor cells in patients with non-small-cell lung cancer

Marianna Gallo, Antonella De Luca, Monica Rosaria Maiello, Amelia D’Alessio, Claudia Esposito, Nicoletta Chicchinelli, Laura Forgione, Maria Carmela Piccirillo, Gaetano Rocco, Alessandro Morabito, Gerardo Botti, Nicola Normanno

Integrating immunotherapy into chemoradiation regimens for medically inoperable locally advanced non-small cell lung cancer

Salma K. Jabbour, Abigail T. Berman, Charles B. Simone II

Editorial

An alternative way to initiate Notch1 signaling in non-small cell lung cancer

Yi-Lin Yang, David Jablons, Liang You

Combination MET- and EGFR-directed therapy in MET-overexpressing non-small cell lung cancers: time to move on to better biomarkers?

Fernando C. Santini, Siddharth Kunte, Alexander Drilon

Systematic Review and Meta-analysis

Association of the metformin with the risk of lung cancer: a meta-analysis

Li Wang, Yong Song, Guan-Nan Wu, Dong-Mei Yuan

China Lung Cancer Research Highlight

Dll4/Notch1 signaling from tip/stalk endothelial cell specification to stroma-dependent lung tumor inhibition: a flavor of Dll4/Notch1 pleiotropy in tumor cell biology

Maria Felice Brizzi, Paola Defilippi

Editorials

Dulanermin in cancer therapy: Still much to do

Cristina Quintavalle, Gerolama Condorelli

Review Articles

EGFR molecular testing in African-American non-small cell lung cancer patients - a review of discrepant data

Bradley T. Clifford, Pingfu Fu, Nathan A. Pennell, Balazs Halmos, Rom S. Leidner

Copy number gains of FGFR1 and 3q chromosome in squamous cell carcinoma of the lung

Pedro Mendez, Jose Luis Ramirez

Role of HGF/MET axis in resistance of lung cancer to contemporary management

Kanwal Pratap Singh Raghav, Ana Maria Gonzalez-Angulo, George R. Blumenschein Jr

Circulating soluble intercellular adhesion Molecule-1 in lung cancer: a systematic review

Xiaoling Gu, Chunyan Ma, Dongmei Yuan, Yong Song

Ceritinib

Clinical development and approval of second generation ALK inhibitors for ALK rearranged lung cancer

Daniel B. Costa

Onartuzumab plus erlotinib

Targeting MET in NSCLC: looking for a needle in a haystack

Lorenza Landi, Federico Cappuzzo

Nivolumab

Nivolumab (anti-PD-1, BMS-936558, ONO-4538) in patients with advanced non-small cell lung cancer

Arun Rajan, James L. Gulley

Brief Report

The role of Imaging and Radiation Oncology Core for precision medicine era of clinical trial

Ying Xiao, Mark Rosen

Review Article on Update on Pathology and Predictive Biomarkers of Lung Cancer

Biology of invasive mucinous adenocarcinoma of the lung

Yoon Jin Cha, Hyo Sup Shim

Immunohistochemistry for predictive biomarkers in non-small cell lung cancer

Mari Mino- Kenudson

Below are the latest Translational Lung Cancer Research articles published online ahead of print publication.

Original Article

Impact of chronic obstructive pulmonary disease on immune checkpoint inhibitor efficacy in advanced lung cancer and the potential prognostic factors

Jiebai Zhou, Yencheng Chao, Danwei Yao, Ning Ding, Jiamin Li, Lei Gao, Yong Zhang, Xiaobo Xu, Jian Zhou, Balazs Halmos, Nikolaos Tsoukalas, Yuki Kataoka, Ramon Andrade de Mello, Yuanlin Song, Jie Hu

A nomogram to predict the overall survival of patients with symptomatic extensive-stage small cell lung cancer treated with thoracic radiotherapy

Xun Yuan, Zhiqin Zheng, Fangfang Liu, Yuan Gao, Wenhui Zhang, Rossana Berardi, Pranshu Mohindra, Zhengfei Zhu, Jie Lin, Qian Chu

Comprehensive analysis of blood-based biomarkers for predicting immunotherapy benefits in patients with advanced non-small cell lung cancer

Cheol-Kyu Park, Hyung-Joo Oh, Min-Seok Kim, Bo-Gun Koh, Hyun-Ju Cho, Young-Chul Kim, Hyung-Jeong Yang, Ji-Young Lee, Sung-Min Chun, In-Jae Oh

Characteristics of hypoxic tumor microenvironment in non-small cell lung cancer, involving molecular patterns and prognostic signature

Zhanghao Huang, Shuo Wang, Hai-Jian Zhang, You Lang Zhou, Xin Tang, Jia-Hai Shi

In small cell lung cancer patients treated with RRx-001, a downregulator of CD47, decreased expression of PD-L1 on circulating tumor cells significantly correlates with clinical benefit

Yusuke Tomita, Bryan Oronsky, Nacer Abrouk, Pedro Cabrales, Tony R. Reid, Min-Jung Lee, Akira Yuno, Jonathan Baker, Sunmin Lee, Jane B. Trepel

In small cell lung cancer patients treated with RRx-001, a downregulator of CD47, decreased expression of PD-L1 on circulating tumor cells significantly correlates with clinical benefit

Yusuke Tomita, Bryan Oronsky, Nacer Abrouk, Pedro Cabrales, Tony R. Reid, Min-Jung Lee, Akira Yuno, Jonathan Baker, Sunmin Lee, Jane B. Trepel

Immune checkpoint inhibitors in oncogene-addicted non-small cell lung cancer: a systematic review and meta-analysis

Giorgia Guaitoli, Marcello Tiseo, Massimo Di Maio, Luc Friboulet, Francesco Facchinetti

First-line immunotherapy in non-small cell lung cancer patients with poor performance status: a systematic review and meta-analysis

Francesco Facchinetti, Massimo Di Maio, Fabiana Perrone, Marcello Tiseo

Review Article

Lung cancer screening: targeting the hard to reach—a review

Guido Van Hal, Paloma Diab Garcia

Lung cancer screening: who pays? who receives?—the Chinese perspective

Yang Zhang, Haiquan Chen

Integrating endobronchial ultrasound bronchoscopy with molecular testing of immunotherapy biomarkers in non-small cell lung cancer

Steven Bozinovski, Amanda Vannitamby, Kanishka Rangamuwa, Savreet Aujla, Hao Wang, Christian Aloe, Louis Irving, Tracy T. Leong, Daniel P. Steinfort

The radiologist’s role in lung cancer screening

Annemiek Snoeckx, Caro Franck, Mario Silva, Mathias Prokop, Cornelia Schaefer-Prokop, Marie-Pierre Revel

Immunotherapy in small cell lung cancer: one step at a time: a narrative review

Daphne W. Dumoulin, Anne-Marie C. Dingemans, Joachim G. J. V. Aerts, Jordi Remon, Dirk K. M. De Ruysscher, Lizza E. L. Hendriks

Immunotherapy in oncogene addicted non-small cell lung cancer

Luke McLean, Jose Luis Leal, Benjamin J. Solomon, Thomas John

Thermal ablation in non-small cell lung cancer: a review of treatment modalities and the evidence for combination with immune checkpoint inhibitors

Kanishka Rangamuwa, Tracy Leong, Clare Weeden, Marie-Liesse Asselin-Labat, Steven Bozinovski, Michael Christie, Tom John, Phillip Antippa, Louis Irving, Daniel Steinfort

Ongoing challenges in implementation of lung cancer screening

Katharina Martini, Guillaume Chassagnon, Thomas Frauenfelder, Marie-Pierre Revel

Lung cancer screening: who pays? Who receives? The European perspectives

Pierluigi Novellis, Silvia Raimondi Cominesi, Francesca Rossetti, Michele Mondoni, Vanesa Gregorc, Giulia Veronesi

Clinical prognostic factors in surgically treated oligometastatic non-small cell lung cancer: a systematic review

Luca Bertolaccini, Monica Casiraghi, Giulia Sedda, Filippo de Marinis, Lorenzo Spaggiari

Emerging and multifaceted role of neutrophils in lung cancer

Christian Aloe, Hao Wang, Ross Vlahos, Louis Irving, Daniel Steinfort, Steven Bozinovski

The person behind the nodule: a narrative review of the psychological impact of lung cancer screening

Samantha L. Quaife, Samuel M. Janes, Kate E. Brain

A narrative review on tumor microenvironment in oligometastatic and oligoprogressive non-small cell lung cancer: a lot remains to be done

Lorenzo Belluomini, Alessandra Dodi, Alberto Caldart, Dzenete Kadrija, Marco Sposito, Miriam Casali, Giulia Sartori, Miriam Grazia Ferrara, Alice Avancini, Emilio Bria, Jessica Menis, Michele Milella, Sara Pilotto

Should sublobar resection be offered for screening-detected lung nodules?

Alan D. L. Sihoe

Managing of screening-detected sub-solid nodules—a European perspective

Sara Ricciardi, Richard Booton, Renè Horsleben Petersen, Maurizio Infante, Marco Scarci, Giulia Veronesi, Giuseppe Cardillo

Artificial intelligence for detection and characterization of pulmonary nodules in lung cancer CT screening: ready for practice?

Anton Schreuder, Ernst T. Scholten, Bram van Ginneken, Colin Jacobs

Novel patterns of progression upon immunotherapy in other thoracic malignancies and uncommon populations

Roberto Ferrara, Diego Signorelli, Claudia Proto, Arsela Prelaj, Marina Chiara Garassino, Giuseppe Lo Russo

B cells in lung cancer—not just a bystander cell: a literature review

Tracy L. Leong, Vanessa L. Bryant

Local ablative therapies in oligometastatic NSCLC-upfront or outback?—a narrative review

Michael C. Tjong, Alexander V. Louie, Puneeth Iyengar, Benjamin J. Solomon, David A. Palma, Shankar Siva

Lung cancer screening in Europe: where are we in 2021?

Jan P. van Meerbeeck, Caro Franck

Managing screening-detected subsolid nodules—the Asian perspective

Masaaki Sato, Shun-Mao Yang, Dong Tian, Nakajima Jun, Jang-Ming Lee

Is there any opportunity for immune checkpoint inhibitor therapy in non-small cell lung cancer patients with brain metastases?

Lizza E. L. Hendriks, Jordi Remon, Jessica Menis, Benjamin Besse

Current and future biomarkers for outcomes with immunotherapy in non-small cell lung cancer

Boris Duchemann, Jordi Remon, Marie Naigeon, Lydie Cassard, Jean Mehdi Jouniaux, Lisa Boselli, Jonathan Grivel, Edouard Auclin, Aude Desnoyer, Benjamin Besse, Nathalie Chaput

Exploring the immune-checkpoint inhibitors’ efficacy/tolerability in special non-small cell lung cancer (NSCLC) populations: focus on steroids and autoimmune disease

Francesco Passiglia, Valeria Cetoretta, Marco De Filippis, Valerio Napoli, Silvia Novello

Exploring natural killer cell immunology as a therapeutic strategy in lung cancer

Jonas B. Hess, Kate D. Sutherland, Sarah A. Best

Radiotherapy for oligometastatic non-small cell lung cancer: a narrative review

Nora Sundahl, Yolande Lievens

A narrative review of combined stereotactic ablative radiotherapy and immunotherapy in metastatic non-small cell lung cancer

Zarique Z. Akanda, Paul J. Neeson, Thomas John, Stephen Barnett, Gerard G. Hanna, Alistair Miller, Ross Jennens, Shankar Siva

How to optimize the incorporation of immunotherapy in trials for oligometastatic non-small cell lung cancer: a narrative review

Jordi Remon, Jessica Menis, Antonin Levy, Dirk K. M. De Ruysscher, Lizza E. L. Hendriks

Liquid biopsy in non-small cell lung cancer—current status and future outlook—a narrative review

Elisabeth Smolle, Valentin Taucher, Jörg Lindenmann, Martin Pichler, Freyja-Maria Smolle-Juettner

The knowns & unknowns of pulmonary toxicity following immune checkpoint inhibitor therapies: a narrative review

Alistair R. Miller, Renee Manser

Screen-detected solid nodules: from detection of nodule to structured reporting

Mario Silva, Gianluca Milanese, Roberta E. Ledda, Ugo Pastorino, Nicola Sverzellati

Holding our breath: the promise of tissue-resident memory T cells in lung cancer

Claire Marceaux, Clare E. Weeden, Claire L. Gordon, Marie-Liesse Asselin-Labat

Editorial

Local for advanced, is this a paradox?

Maristella Bungaro, Chiara Paratore, Paolo Bironzo, Silvia Novello

Journal Highlight more

Translational Lung Cancer Research is an international, peer-reviewed, open-access journal indexed by Science Citation Index Expanded (SCIE) and PubMed/PubMed Central, focusing on cutting-edge development on the transition from preclinical to clinical research, including but not limited to multimodality therapy, markers, imaging, tumor biology, pathology, chemoprevention, and technical advances related to lung cancer and relevant thoracic diseases.